文献速递肿瘤 PET/CT核素与放射性配体治疗

新型雄激素受体靶向PET显像在前列腺癌中的临床前及首次人体评估

Preclinical and first-in-human evaluation of novel androgen receptor-targeted PET imaging in prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-09-23

本研究合成三种68Ga标记的恩杂鲁胺(Enzalutamide)基PET示踪剂,在体外和荷瘤小鼠中验证其雄激素受体(AR)特异性,并对[68Ga]Ga-DOTA-FZAR-2在8例前列腺癌患者中开展首次人体评估,结果显示该示踪剂安全且具有诊断价值,可用于全身动态监测AR表达。

要点

  • 三种68Ga标记恩杂鲁胺基示踪剂放射化学纯度均超过99%,体外稳定性良好。
  • 细胞摄取与AR表达水平强相关(P < 0.001),LNCaP最高、22Rv1居中、PC-3最低。
  • [68Ga]Ga-DOTA-FZAR-2在8例前列腺癌患者中显示安全性和诊断价值。

核心结论

  • 成功开发并验证了一系列68Ga标记的恩杂鲁胺基PET示踪剂用于AR显像。
  • 初步临床前和临床证据表明[68Ga]Ga-DOTA-FZAR-2可实现前列腺癌患者治疗全程的无创、全身、动态AR表达监测。

研究设计与样本

  • 临床前研究:合成[68Ga]Ga-DOTA-FZAR-1、[68Ga]Ga-DOTA-FZAR-2和[68Ga]Ga-DOTAGA-FZAR-3,在AR阴性和AR阳性前列腺癌细胞系及荷瘤小鼠中评估AR特异性。
  • 首次人体评估:[68Ga]Ga-DOTA-FZAR-2在8例前列腺癌患者中进行。

主要发现

  • 三种示踪剂放射化学纯度均超过99%,体外稳定性良好。
  • 细胞摄取实验显示LNCaP、22Rv1和PC-3细胞摄取分别最高、居中、最低,与AR表达水平强相关(P < 0.001)。
  • 荷瘤小鼠肿瘤摄取呈与细胞摄取一致的分层模式:LNCaP最高、22Rv1居中、PC-3最低。
  • 离体生物分布研究证实三种示踪剂主要经泌尿系统清除。
  • 首次人体研究显示[68Ga]Ga-DOTA-FZAR-2在AR相关前列腺癌患者中具有安全性和诊断价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Activation of androgen receptor (AR) signaling is a hallmark of prostate cancer. Dynamic changes in AR expression exacerbate AR heterogeneity throughout prostate cancer therapy. This study aims to develop a series of 68Ga-labeled Enzalutamide-based positron emission tomography (PET) tracers for AR imaging. METHODS: [68Ga]Ga-DOTA-FZAR-1, [68Ga]Ga-DOTA-FZAR-2, and [68Ga]Ga-DOTAGA-FZAR-3 were synthesized and the stability was analyzed in vitro. The AR specificity of the three radiotracers was assessed in vitro using AR-negative and AR-positive prostate cancer cell lines and in vivo using tumor xenograft-bearing mice. Moreover, the first-in-human evaluation of [68Ga]Ga-DOTA-FZAR-2 was conducted in eight patients with prostate cancer. RESULTS: [68Ga]Ga-DOTA-FZAR-1, [68Ga]Ga-DOTA-FZAR-2, and [68Ga]Ga-DOTAGA-FZAR-3 were successfully synthesized with a radiochemical purity of more than 99%, and had good stability in vitro. Cellular uptake assays revealed that the radiotracers had the highest, intermediate, and lowest uptake in LNCaP, 22Rv1, and PC-3 cells, respectively, strongly correlating with AR expression levels (P < 0.001). Consistent with cellular uptake, the radiotracers also exhibited a hierarchical uptake pattern (highest to lowest) in tumors of mice bearing LNCaP, 22Rv1 and PC-3 xenografts, respectively. In addition, all three radiotracers were primarily eliminated through the urinary system, as confirmed by ex vivo biodistribution studies. More importantly, first-in-human investigation showed safety and diagnostic value of [68Ga]Ga-DOTA-FZAR-2 in AR-associated prostate cancer patients. CONCLUSION: We developed and validated a series of 68Ga-labeled Enzalutamide-based PET tracers for AR imaging. Initial preclinical and clinical evidence indicate that [68Ga]Ga-DOTA-FZAR-2 enables noninvasive, whole-body, and dynamic monitoring of AR expression in prostate cancer patients throughout therapy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lin S, Wang X, Wan F, et al. Preclinical and first-in-human evaluation of novel androgen receptor-targeted PET imaging in prostate cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 40986091. doi:10.1007/s00259-025-07577-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。